PREVENT ALL ALS Study
NCT06581861
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT Number: NCT06578195
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The clinical sites are distributed across the country, and led by a group of collaborative principal investigators. Once data and samples are collected and harmonized, it will be made available to research community for future research into ALS and related neurological diseases.
ASSESS protocol is specific for symptomatic ALS and control participants. This protocol includes both on-site and off-site(remote) participants. The participants will be followed for 24 months (2 years), and will include collection of medical history, clinical outcomes, and blood samples once in 4 months. Additionally, the participants will complete patient reported outcomes and speech recordings once a month. Participants who are coming into clinic may also provide optional Cerebrospinal Fluid (CSF) samples.
Interested in participating?
Request Info18 year and older
All sexes
Observational
CHALS-CCT, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for ALS participants:
Inclusion criteria
for control participants:
Exclusion criteria
for all participants:
Exclusion criteria
for participants undergoing optional Lumbar Puncture
Time frame: Baseline, 4, 8, 12, 16, 20 and 24 months for ALS participants only.
Questionnaire administered by a clinician that includes a series of questions about participants' ability to function in certain daily activities. Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.
Time frame: Baseline, 2, 4 ,6, 8, 10, 12, 14,16, 18,20, 22 and 24 months for ALS participants only
Questionnaires completed by participants that includes questions about participants ability to function in certain daily activities. Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.
Time frame: 1, 3, 5,7,9,11,13,15,17,19,21 and 23 months from baseline for ALS participants only
Questionnaires completed by participants that assess severity of the ALS disease
Time frame: Months 3 and 4 for all cohorts
Questionnaires completed by participants that includes questions about non-medical factors that affect health outcomes
Time frame: Month 1 for all cohorts
Questionnaires completed by participants that includes questions about environmental exposures such as chemicals, smoking, alcohol etc.
Time frame: Baseline, 12 and 24 months for all cohorts
ECAS is a multi-domain assessment administered by study staff, to evaluate different aspects of cognitive function
Time frame: Baseline, 4,8,12,16,20 and 24 months for on-site ALS participants; Baseline, 12 and 24 months for control participants
Change in respiratory function over time as measured by Slow Vital Capacity (SVC).
Time frame: Baseline, and monthly (at month 1,2, 3 through month 24 from baseline)
Participants will be asked to record voice samples at home once a month using a digital application installed on their device.
Time frame: Baseline, 4,8,12,16,20 and 24 months for on-site ALS participants; Baseline, 12 and 24 months for control participants
Hand-held dynamometry (HHD) will be used as a quantitative measure of muscle strength for the three intrinsic hand muscles, bilaterally
Contact information is provided by the study sponsor or research team.
St. Joseph's Hospital and Medical Center, Phoenix
Other
ASSESS ALL ALS - Longitudinal Biomarker Study for Symptomatic ALS and Control Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06581861
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT04363684
Amyotrophic Lateral Sclerosis, Basal Ganglia Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06284161
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Clermont-Ferrand, France
View Trial DetailsNCT03225144
Amyotrophic Lateral Sclerosis, Basal Ganglia Diseases
Bethesda, Maryland, United States
View Trial Details